Hitomi S. Okuma

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Integrating DNA Mutations and RNA Expression of Cancer Driver Genes in Asian Rare Cancers: A Pan-Cancer Analysis.

Integrating DNA Mutations and RNA Expression of Cancer Driver Genes in Asian Rare Cancers: A Pan-Cancer Analysis.

Journal: JCO precision oncology

Published: June 29, 2026

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis.

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis.

Journal: Blood cancer journal

Published: December 15, 2025

Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.

Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.

Journal: Cancer discovery

Published: October 07, 2025

Real-world characterization of patients with advanced or metastatic liposarcoma, including dedifferentiated liposarcoma, in Japan in the MASTER KEY project.

Real-world characterization of patients with advanced or metastatic liposarcoma, including dedifferentiated liposarcoma, in Japan in the MASTER KEY project.

Journal: Japanese journal of clinical oncology

Published: September 04, 2025

FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan-Asian Study.

FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan-Asian Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 12, 2025

Baseline risk variability by eligibility criteria in Cohort 1 of the monarchE trial for high-risk HR-positive, HER2-negative breast cancer.

Baseline risk variability by eligibility criteria in Cohort 1 of the monarchE trial for high-risk HR-positive, HER2-negative breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: April 19, 2025

Treatment and Reasons for Choosing Treatment in Breast Cancer Patients Who Underwent Next-Generation Sequencing Test.

Treatment and Reasons for Choosing Treatment in Breast Cancer Patients Who Underwent Next-Generation Sequencing Test.

Journal: Oncology

Published: October 24, 2024

Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum-Based Therapy.

Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum-Based Therapy.

Journal: Head & neck

Published: September 13, 2024

Cancer registry as external control data for regulatory submission in Japan.

Cancer registry as external control data for regulatory submission in Japan.

Journal: ESMO real world data and digital oncology

Published: September 13, 2024

Planning and Implementing Master Protocol Trials in Japan: Key Considerations of the Japanese Guideline.

Planning and Implementing Master Protocol Trials in Japan: Key Considerations of the Japanese Guideline.

Journal: Clinical pharmacology and therapeutics

Published: July 10, 2024

Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.

Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.

Journal: Breast cancer (Tokyo, Japan)

Published: March 18, 2024

Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis.

Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis.

Journal: Anticancer research

Published: March 01, 2024

Showing 1-12 of 51

Last Updated: 09/26/2026